Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kann als monotherapie oder in kombination mit methotrexat verwendet werden. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - brustgeschwulste - antineoplastische mittel - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - glucagon - diabetes mellitus - pankreas-hormone, hormone glycogenolytic - baqsimi ist indiziert für die behandlung von schwerer hypoglykämie bei erwachsenen, jugendlichen und kindern im alter von 4 jahren und älter mit diabetes mellitus.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastische mittel - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colitis, ulzerativ - immunsuppressiva - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Kesatuan Eropah - Jerman - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - lymphom, mantelzell - protein-kinase-inhibitoren - treatment of mantle cell lymphoma (mcl).

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mibe gmbh arzneimittel (8004658) - metoprololsuccinat (ph.eur.) - retardtablette - metoprololsuccinat (ph.eur.) (11953) 190 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mibe gmbh arzneimittel (8004658) - metoprololsuccinat (ph.eur.) - retardtablette - metoprololsuccinat (ph.eur.) (11953) 95 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mibe gmbh arzneimittel (8004658) - metoprololsuccinat (ph.eur.) - retardtablette - metoprololsuccinat (ph.eur.) (11953) 47,5 milligramm

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mibe gmbh arzneimittel (8004658) - metoprololsuccinat (ph.eur.) - retardtablette - metoprololsuccinat (ph.eur.) (11953) 23,75 milligramm